4//SEC Filing
Dambkowski Carl 4
Accession 0001104659-26-002574
CIK 0001974640other
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 8:00 PM ET
Size
15.4 KB
Accession
0001104659-26-002574
Insider Transaction Report
Form 4
Dambkowski Carl
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-07$22.86/sh+14,025$320,612→ 231,223 total - Sale
Common Stock
2026-01-07$77.13/sh−2,954$227,842→ 228,269 total - Sale
Common Stock
2026-01-07$77.90/sh−14,820$1,154,478→ 213,449 total - Sale
Common Stock
2026-01-07$79.04/sh−826$65,287→ 212,623 total - Sale
Common Stock
2026-01-07$80.06/sh−100$8,006→ 212,523 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−14,025→ 139,540 totalExercise: $22.86Exp: 2033-12-18→ Common Stock (14,025 underlying)
Footnotes (6)
- [F1]Due to an administrative error, the amount reported in Column 5 on the reporting person's Form 4 filed on October 3, 2025 was overstated by 53,910 shares. As a result, the beneficial ownership totals reported in the reporting person's Forms 4 filed after October 3, 2025 were each overstated by 53,910 shares. This Form 4 reflects the correct amount of common stock beneficially owned by the reporting person.
- [F2]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $76.44 to $77.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.45 to $78.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.70 to $79.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.
Documents
Issuer
Apogee Therapeutics, Inc.
CIK 0001974640
Entity typeother
Related Parties
1- filerCIK 0001983476
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 8:00 PM ET
- Size
- 15.4 KB